Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited, dated June 10, 2024, serves as a partial correction to the Notice of Convocation for the 148th Ordinary General Meeting of Shareholders. The filing addresses specific errors in the "Reference Document for the General Meeting of Shareholders" regarding the Second Proposal.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly an administrative correction regarding share allocations and contains no financial performance data.
Material Changes
The material change reported is a correction to the number of Company American Depositary Shares (ADS) to be provided to two executives as part of the Second Proposal:
- Mr. Christophe Weber: The number of ADS was corrected from 211,756 shares to 211,810 shares.
- Dr. Andrew Plump: The number of ADS was corrected from 739,162 shares to 739,658 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the correction of share counts for the upcoming shareholder meeting.
Investor Verification Checklist
- Verify the corrected ADS allocation figures for Mr. Christophe Weber (211,810 shares) and Dr. Andrew Plump (739,658 shares) in the updated Reference Document.
- Confirm the impact of these corrected share counts on the total equity dilution or compensation expense, if disclosed in the full Reference Document.
- Ensure the corrected Notice of Convocation is reflected in all shareholder communications prior to the 148th Ordinary General Meeting.